Sanofi-Aventis Pty Ltd

Regulatory activities for this sponsor.

3 result(s) found, displaying 1 to 3

AusPAR: Inactivated quadrivalent influenza vaccine (split virion) influenza virus haemagglutinin

27 November 2020

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Inactivated quadrivalent influenza vaccine (split virion) influenza virus haemagglutinin
Libtayo

29 July 2020

Prescription medicine decision summary

Libtayo (cemiplimab) is provisionally approved to treat cutaneous squamous cell carcinoma in adults
Sarclisa

14 May 2020

Prescription medicine decision summary

Australian prescription medicine decision summary